Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin and CPAP in Heart Failure and Obstructive Sleep Apnea
NCT07556094Completed
- Sponsor
- Medical University of Białystok
- Start
- Jun 2023
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of empagliflozin in obstructive sleep apnea (OSA) and heart failure (HF) (2 arms), sponsored by Medical University of Białystok. Primary endpoint: Apnea-Hypopnea Index at 6 months. Started Jun 2023; status: completed.
02
Drugs
empagliflozin
03
Conditions
obstructive sleep apnea (OSA)heart failure (HF)
Beyond the preview
Go deeper on NCT07556094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07556094.